坎托菲茨杰拉德公司：維持Prothena Corp(PRTA.US)增持評級, 目標價由91.00美元調整至98.00美元。 Prothena（PRTA.US）公司簡介：Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and...
坎托菲茨杰拉德公司：維持Prothena Corp(PRTA.US)增持評級, 目標價由91.00美元調整至98.00美元。
Prothena（PRTA.US）公司簡介：Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm抯 clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer抯 disease, Parkinson抯 disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
以上內容由證券之星根據公開信息整理，與本站立場無關。證券之星力求但不保證該信息（包括但不限于文字、視頻、音頻、數據及圖表）全部或者部分內容的的準確性、完整性、有效性、及時性等，如存在問題請聯系我們。本文為數據整理，不對您構成任何投資建議，投資有風險，請謹慎決策。
jay
